Preparation, characterization, and topical delivery of paromomycin ion pairing

Drug Development and Industrial Pharmacy

Volumn 37, Issue 9, 2011, Pages 1083-1089

  Nogueira, Isabel R L ^a   Carneiro, Guilherme ^a   Yoshida, Maria Irene ^a   De Oliveira, Renata B ^a   Ferreira, Lucas A M ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Cutaneous leishmaniasis; Ion pairing; Paromomycin; Skin penetration; Topical treatment

Indexed keywords

CARBOXYLIC ACID; PAROMOMYCIN; PAROMOMYCIN BENZOATE; PAROMOMYCIN BUTYRATE; PAROMOMYCIN CINNAMATE; PAROMOMYCIN LACTATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BACILLUS SUBTILIS; DRUG PENETRATION; DRUG SOLUBILITY; DRUG SYNTHESIS; IN VITRO STUDY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SKIN PENETRATION; STRUCTURE ACTIVITY RELATION; SWINE; THERMAL ANALYSIS;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTI-BACTERIAL AGENTS; IONS; LEISHMANIASIS, CUTANEOUS; MODELS, ANIMAL; PAROMOMYCIN; PERMEABILITY; SKIN; SWINE;

EID: 79961135971     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.559660     Document Type: Article

References (21)

1. Desjeux P. (2004). Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis, 27:305-318. (Pubitemid 38842803)
2. Grevelink SA, Lerner EA. (1996). Leishmaniasis. J Am Acad Dermatol, 34:257-272. (Pubitemid 26063997)
3. Croft SL, Coombs GH. (2003). Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol, 19:502-508. (Pubitemid 37329659)
4. Garnier T, Croft SL. (2002). Topical treatment for cutaneous leishmaniasis. Curr Opin Investig Drugs, 3:538-544.
5. Soto JM, Toledo JT, Gutierrez P, Arboleda M, Nicholls RS, Padilla JR et al. (2002). Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg, 66:147-151. (Pubitemid 34755645)
6. Neal RA, Allen S, McCoy N, Olliaro P, Croft SL. (1995). Te sensitivity of Leishmania species to aminosidine. J Antimicrob Chemother, 35:577-584.
7. Ben Salah A, Zakraoui H, Zaatour A, Ftaiti A, Zaafouri B, Garraoui A et al. (1995). A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am J Trop Med Hyg, 53:162-166.
8. Asilian A, Jalayer T, Whitworth JA, Ghasemi RL, Nilforooshzadeh M, Olliaro P. (1995). A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg, 53:648-651. (Pubitemid 26036354)
9. Soto J, Fuya P, Herrera R, Berman J. (1998). Topical paromomycin/ methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Clin Infect Dis, 26:56-58. (Pubitemid 28068155)
10. Sarveiya V, Templeton J F, Benson HA. (2005). Efect of lipophilic counter-ions on membrane difusion of benzydamine. Eur J Pharm Sci, 26:39-46. (Pubitemid 41097259)
11. Fini A, Fazio G, Gonzalez-Rodriguez M, Cavallari C, Passerini N, Rodriguez L. (1999). Formation of ion-pairs in aqueous solutions of diclofenac salts. Int J Pharm, 187:163-173. (Pubitemid 29443896)
12. Megwa SA, Cross SE, Benson HA, Roberts MS. (2000). Ion-pair formation as a strategy to enhance topical delivery of salicylic acid. J Pharm Pharmacol, 52:919-928.
13. Abu Hena Mostofa Kamal M, Iimura N, Nabekura T, Kitagawa S. (2006). Enhanced skin permeation of salicylate by ion-pair formation in non-aqueous vehicle and further enhancement by ethanol and l-menthol. Chem Pharm Bull, 54:481-484.
14. Lengsfeld CS, Pitera D, Manning M, Randolph TW. (2002). Dissolution and partitioning behavior of hydrophobic ion-paired compounds. Pharm Res, 19:1572-1576. (Pubitemid 35266565)
15. Jacobi U, Kaiser M, Toll R, Mangelsdorf S, Audring H, Otberg N et al. (2007). Porcine ear skin: an in vitro model for human skin. Skin Res Technol, 13:19-24. (Pubitemid 46152448)
16. Sekkat N, Kalia YN, Guy RH. (2004). Development of an in vitro model for premature neonatal skin: biophysical characterization using transepidermal water loss. J Pharm Sci, 93:2936-2940. (Pubitemid 39657797)
17. Barbieri CM, Pilch DS. (2006). Complete thermodynamic characterization of the multiple protonation equilibria of the aminoglycoside antibiotic paromomycin: a calorimetric and natural abundance 15N NMR study. Biophys J, 90:1338-1349.
18. Ferreira LS, Ramaldes GA, Nunan EA, Ferreira LA. (2004). In vitro skin permeation and retention of paromomycin from liposomes for topical treatment of the cutaneous leishmaniasis. Drug Dev Ind Pharm, 30:289-296. (Pubitemid 38451753)
19. Lopes LB, Lopes JL, Oliveira DC, Tomazini JA, Garcia MT, Fantini MC et al. (2006). Liquid crystalline phases of monoolein and water for topical delivery of cyclosporin A: characterization and study of in vitro and in vivo delivery. Eur J Pharm Biopharm, 63:146-155. (Pubitemid 43776220)
20. Weigmann HJ, Ulrich J, Schanzer S, Jacobi U, Schaefer H, Sterry W et al. (2005). Comparison of transepidermal water loss and spectroscopic absorbance to quantify changes of the stratum corneum after tape stripping. Skin Pharmacol Physiol, 18:180-185. (Pubitemid 40869129)
21. Carneiro G, Santos DC, Oliveira MC, Fernandes AP, Ferreira LS, Ramaldes GA et al. (2010). Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis. J Liposome Res, 20:16-23.